Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study

K Kido, S Hatakeyama, K Numakura, T Tanaka… - International Journal of …, 2021 - Springer
Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …
被引用次数：11 相关文章

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.

K Kido, S Hatakeyama, K Numakura… - … Journal of Clinical …, 2021 - search.ebscohost.com
Background: This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …

[引用][C] Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective …

K Kido, S Hatakeyama, K Numakura, T Tanaka… - International Journal of …, 2020 - cir.nii.ac.jp
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies
for metastatic renal-cell carcinoma: a multicenter retrospective study | CiNii Research CiNii …

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study

K Kido, S Hatakeyama, K Numakura… - … journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.

K Kido, S Hatakeyama, K Numakura… - … Journal of Clinical …, 2020 - europepmc.org
Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study

K Koichi, H Shingo, N Kazuyuki… - … Journal of Clinical …, 2021 - search.proquest.com
Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …